Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jun 13, 2013Former Secretary of State and Epilepsy Advocate Hillary Rodham Clinton to Speak as This Year's Guest of Honor
Eisai Inc. announced today its platinum level sponsorship of the Citizens United for Research in Epilepsy (CURE) 15th Annual Chicago Benefit...
Jun 7, 2013BELVIQ Available in U.S. Pharmacies within One WeekWOODCLIFF LAKE, NJ, June 7, 2013 /PRNewswire/ — Eisai Inc. announced today that BELVIQ (pronounced BEL-VEEK) will be available to eligible patients by prescription in the United States...
-
May 8, 2013
Eisai Inc. announced today that the U.S. Drug Enforcement Administration (DEA) has placed BELVIQ (pronounced BEL-VEEK) into Schedule IV of the...
-
Apr 18, 2013-- 4 Paws for Ability Service Dogs to Greet Visitors at Eisai Event Booth --
Woodcliff Lake, NJ - April 18, 2013 - Eisai Inc. announced today that it is a silver level sponsor of the Epilepsy Foundation's 7th Annual National Walk for Epilepsy, a family-oriented,...
-
Mar 26, 2013
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved ACIPHEX(®) Sprinkle™ Delayed-Release Capsules 5mg...
-
Dec 11, 2012
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) determined that Eisai has met the FDA's Written Request requirements...
-
Nov 30, 2012
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review Eisai's New Drug Application (NDA)...
-
Nov 8, 2012Eisai Recognizes Inaugural LGS Awareness Day and Epilepsy Awareness Month with Launch of New Caregiver Support Video
With approximately two million people in the United States living with epilepsy, including a severe and rare form called Lennox-Gastaut syndrome...
-
Oct 22, 2012-- FYCOMPA is the First FDA-Approved Non-competitive AMPA Glutamate Receptor Antagonist --
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved FYCOMPA (perampanel) as an adjunctive treatment for...
-
Aug 20, 2012
Eisai Inc. announced today that the results of two studies: "Evaluation of Adjunctive Perampanel in Patients with Refractory Partial Onset...